|
English
|
正體中文
|
简体中文
|
2826152
|
|
???header.visitor??? :
31818821
???header.onlineuser??? :
1266
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"alsina m"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
|
Reynolds K.L; Bedard P.L; Lee S.-H; Chia-Chi Lin; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham D.M; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang Y.-J. |
| 國家衛生研究院 |
2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad
|
Denlinger, CS;Sym, SJ;Bendell, JC;Alsina, M;Watkins, D;Chao, Y;Cubillo, A;Kunz, PL;Sun, WJ;Baeksgaard, L;Chen, LT;Horgan, K;Frye, S;Kudia, AJ;McDonagh, CF;Czibere, AG;Moyo, VM;Chibaudel, B;Bang, YJ |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
